Advertisement

Topics

DMD patients in the UK win early access to Santhera’s Raxone

05:50 EDT 22 Jun 2017 | PharmaTimes

Santhera Pharmaceuticals’ Raxone has become the first drug for Duchenne Muscular Dystrophy (DMD) to join the UK’s Early Access to Medicines Scheme (EAMS).

Original Article: DMD patients in the UK win early access to Santhera’s Raxone

NEXT ARTICLE

More From BioPortfolio on "DMD patients in the UK win early access to Santhera’s Raxone"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...